Owing to these literature data, the role of NLRP3 in the development of AKI and progression toward CKD, and a preliminary study reporting beneficial effects of ibrutinib in cerebral ischemia-induced fibrosis, we hypothesized that BTK inhibition may reduce the severity of AKI and prevent the development of renal fibrosis. Here, NLRP3 is linked to chronic kidney disease.